Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment...

by H. Midgard, A. K. Finbråten, K. B. Malme, R. M. Berg-Pedersen, L. Tanum, I. C. Olsen, R. Bjørnestad, O. Dalgard
Published 2020-06-01

O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study

by G. Dore, J. Grebely, F. Altice, A.H. Litwin, O. Dalgard, E.J. Gane, O. Shibolet, A. Luetkemeyer, R. Nahass, C.Y. Peng, B. Conway, D.M. Iser, H.C. Huang, I.N. Gendrano, M. Kelly, P. Hwang, M. Robertson, J. Wahl, E. Barr, H.L. Platt
Published 2017-08-01

O13 Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study

by J. Grebely, O. Dalgard, B. Conway, E. Cunningham, P. Bruggmann, B. Hajarizadeh, J. Amin, P. Marks, S. Quiene, T.L. Applegate, T. Swan, J. Byrne, M. Lacalamita, A. Dunlop, J. Bruneau, M.E. Hellard, G.V. Matthews, J. Powis, D. Shaw, M.C. Thurnheer, M. Weltman, I. Kronborg, C. Cooper, J.J. Feld, C. Fraser, A. Litwin, J. Dillon, P. Read, E. Gane, G.J. Dore
Published 2017-08-01